The LUCENT studies are a family of Phase III clinical research trials that will assess whether the study drug, called mirikizumab, can induce and maintain clinical remission in patients with moderate to severe ulcerative colitis, for which conventional and/or biologic treatments have not helped.

The LUCENT studies are comprised of a 12-week induction study (LUCENT 1), a 40-week maintenance study (LUCENT 2) and up to a 3 year open-label extension study (LUCENT 3).

The LUCENT 1 and LUCENT 2 studies will compare the study drug with placebo (which looks the same as the study drug but contains no active medication). These studies are blinded, which means that neither you nor the study doctor will know whether you are taking the study drug or placebo. In the LUCENT 3 study all participants will receive the study drug.

Primary inclusion criteria for LUCENT studies:

  • Have active UC 
  • Are between 18 and 80 years old
  • Have not been helped by previous or current treatments

All trial-related medications and procedures will be provided at no cost to you. Reasonable trial-related expenses (such as travel) will also be reimbursed.

Do I Qualify?

Learn More

Preview Image

About Ulcerative Colitis

Preview Image

Find out if you qualify by answering a few questions today.